SOL-116 a drug candidate with groundbreaking potential

Lipum’s drug candidate SOL-116 is a humanized antibody expected to offer a unique mechanism of action for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA). Our goal is for SOL-116 to alleviate painful symptoms and improve the quality of life for the millions of patients suffering from chronic inflammatory diseases.

Lipum has completed and published the Clinical Study Report (CSR) for its First-in-Human (FIH) Phase I trial evaluating SOL-116. The study investigated single ascending doses (SAD) and multiple doses (MD) of SOL-116 in healthy volunteers, as well as a single dose in patients with mild rheumatoid arthritis (RA), and the findings support further clinical development for potential rheumatoid arthritis therapy. Read more about the study results here »

The story behind Lipum

Lipum AB (publ) was originally founded based on a discovery made by scientists at Umeå University. The history of the innovation goes back to the 1970s when Olle Hernell, Prof. of Pediatrics and his group was studying breast milk and the role of a lipase in the milk supporting efficient digestion of the milk fat in breastfed infants, an enzyme they gave the name Bile Salt-Stimulated Lipase (BSSL).